The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
 
Egbert F. Smit
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly; Merck KGaA (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Joop De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); MSD Oncology (Inst); Roche (Inst)
 
Harm van Tinteren
No Relationships to Disclose